Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
about
Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphomaLong-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantationFrontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study GroupTreatment of peripheral T-cell lymphoma: are we data driven or driving the data?Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Peripheral T-cell lymphoma: review and updates of current management strategiesTreatment of High-Risk T-NHL with Stem Cell Transplantation: A Single Center Experience.Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.No survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 cases.Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy.Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsAn update on the management of peripheral T-cell lymphoma and emerging treatment optionsNew developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.The role of allogeneic transplantation in non-Hodgkin's lymphoma.The graft-versus-lymphoma effect: clinical review and future opportunities.Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond.Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant researchHematopoietic stem cell transplantation in peripheral T-cell lymphomas.Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Controversies in the treatment of lymphoma with autologous transplantation.Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas.Transplantation for non-Hodgkin lymphoma.New drug therapies in peripheral T-cell lymphoma.Brentuximab vedotin for the treatment of CD30+ lymphomas.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Treatment algorithms for mature T-cell and natural killer-cell neoplasms.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Hematopoietic cell transplantation for lymphomas.Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status
P2860
Q26999011-E3A6FD86-D0C1-45CA-A52B-C8D7C65E91FDQ28254421-8B2F00A4-BC2E-49AA-BB15-960E2D5D254BQ28307793-C7F7848A-B9E4-4184-AAED-D2E9140352FBQ30613674-0B717B2E-9A6C-49C6-9D4F-175DDB934BD9Q33396356-5C3E2C56-69E6-4283-838E-DA22F22B1024Q33745878-845BCE6C-9EFB-4319-B8E5-E41E6661B45DQ33952823-4F11D324-6A0C-4A1C-82BD-CA7A70422108Q34307446-105868B2-EEFB-4884-9015-2E26F43A345FQ34370320-7F00B1BF-3DBA-491E-AED4-FC2198E6FD5DQ34479082-964562D9-512D-44AD-8049-C90769F7932DQ34766846-2B9B913A-C208-4987-AC76-05FD686D0FB7Q35061893-CAC035AB-1567-4792-A147-750D36ACFE88Q35064713-47B00BEC-CE18-4C37-8625-142E8054429FQ35087581-015BA05E-B8D6-48B6-AF94-A2DB2DDDA04BQ35126129-8EBD1BF1-E639-404A-8955-65E5F1648985Q35219963-A8000081-1EC4-40E5-9FA5-D19C5C8C967AQ35232848-2821CAF8-CA2B-41DB-98EF-C895699DC88DQ35683871-30F1CABF-681D-4E91-A0F1-F8A1334E56EBQ35703714-5CFB5E81-87AA-4FAC-ABB0-E349E0391B3CQ36003103-A0E96E3B-E423-4DE8-9AB8-CAAAC5C08E15Q36128232-8D2F82C0-2917-497B-BBD7-D53F8432182AQ36231758-2B8E4632-0239-471A-BA0E-AD09626AE362Q36355093-07CCD014-B45D-461E-B556-F52C55831EC3Q36570651-BD6D2FB6-67F0-4A73-A2E2-F090DD89FB94Q36604739-D22499AC-D971-4EAF-BFA0-AF61C25983EEQ36612584-4C2A6FB1-6A6F-41A3-8439-87DAA62A0E34Q36806876-2ED7A229-A5F0-4874-B016-7EC656ABCC87Q36911495-76EC9876-FD04-4163-A6BA-3C381BA0E73FQ37122302-4823E514-0F1C-41F2-A340-CA1B32D51A3EQ37271019-42E1592F-B836-4B0E-8409-AF597447E0F6Q37593800-9352735B-3226-4C91-9E1C-282D4D9B1B8CQ37809085-9E6198D9-9682-4FFF-BD77-BE9E068D9CCDQ37810079-FEFC4493-AF9E-46F3-9E9D-1E0DEB88F422Q37854715-6C12E9BA-7FD4-4AB1-8AE9-07BE18F0F5F5Q37861212-0DF29C69-236F-4496-93F2-8555C3E624DFQ37863688-3F8EBE6F-E337-426F-A4C8-A600FFC7C5BCQ37932546-6D16510B-849A-4F5A-A28C-57C1DE867E8BQ37938531-B47E9C93-C1AC-4823-A21F-2571690DBF00Q37942817-C18C8B78-B71E-4490-9E59-0C3F409E0F7AQ38108320-B6B01442-1559-45BB-91EF-C75D5FDDA225
P2860
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@en
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@nl
type
label
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@en
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@nl
prefLabel
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@en
Graft-versus-lymphoma effect i ...... tation of hematopoietic cells.
@nl
P2093
P50
P356
P1476
Graft-versus-lymphoma effect i ...... ntation of hematopoietic cells
@en
P2093
A Rambaldi
Alessandro M Gianni
Corrado Tarella
Daniele Caracciolo
Fabio Benedetti
Francesca Patriarca
Francesco Zallio
Marco Casini
Mario Boccadoro
P304
P356
10.1200/JCO.2004.12.050
P407
P577
2004-06-01T00:00:00Z